Sort
82,697 grants matching “vaccine development”
Development Of New Approaches To Vaccines Against TBEV and West Nile Virus
$941,022Alexander Pletnev · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
A Comprehensive 5K Plus Glycan Microarray
$940,980Jian Zhang · Z Biotech, Llc · R44 · FY2021 · GM
Immunotherapeutics and vaccines against anthrax, plague and tularemia
$940,978Zheng W Chen · University Of Illinois At Chicago · U01 · FY2009 · AI
University of North Carolina - Chlamydia Vaccine Initiative (UNC-CVI)
$940,955Toni Darville · Univ Of North Carolina Chapel Hill · U19 · FY2020 · AI
Characterization of Proteomes of Category A Pathogens
$940,926Diversa Corporation · U01 · FY2003 · AI
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted Interventions
$940,910Clifford J Rosen · Mainehealth · U54 · FY2021 · GM
Analysis and Modulation of Virus-Host Interaction in Infections of the Liver
$940,899Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
Structural characterization of MPER-TM immunogens
$940,588Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2024 · AI
MAPs for Peds: Development of a Microarray Patch for Delivery of Long-Acting Antiretrovirals for Treatment of Pediatric HIV Infection
$940,558Robert Kwai Ming Choy · Path · R33 · FY2022 · AI
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS
$940,483Charles Houston Jones · Abcombi Biosciences, Inc. · R44 · FY2021 · AI
Immunotherapeutics and vaccines against anthrax, plague and tularemia
$940,299Zheng W Chen · University Of Illinois At Chicago · U01 · FY2006 · AI
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine
$940,253Amit Praful Khandhar · Hdt Bio Corporation · R61 · FY2023 · AI
COBRE Phase III: Transitional Center for Research on Processes in Evolution
$940,199Larry J Forney · University Of Idaho · P30 · FY2017 · GM
Clinical Support
$940,088James J Vredenburgh · Duke University · P01 · FY2015 · CA
Cellular Immunity and Memory to SARS-CoV-2
$940,081Elizabeth B Norton · Tulane University Of Louisiana · U54 · FY2020 · CA
Chemically Programmed Immunity
$940,005Carlos F Barbas · Scripps Research Institute, The · DP1 · FY2011 · OD
Chemically Programmed Immunity
$940,005Carlos F Barbas · Scripps Research Institute, The · DP1 · FY2012 · CA
IAS 2025. the 13th IAS Conference on HIV Science, Kigali, Rwanda, 14-17 July 2025
$940,000Chris Beyrer · Ias · R13 · FY2025 · AI
CANDIDA ADHERENCE MYCOLOGY RESEARCH UNIT
$939,895La Biomed Res Inst/ Harbor Ucla Med Ctr · P01 · FY2003 · AI
Structural characterization of host-parasite interactions in malaria
$939,894Niraj Tolia · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Mechanisms of effective antibody neutralization of malaria parasites
$939,894Niraj Tolia · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Task 01 (A01): In Vitro Screens for Antimicrobial Activity
$939,865Uk Health Security Agency · N01 · FY2009 · AI
CCR FACS Core Laboratory
$939,713Karen Wolcott · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV
$939,695Valerian Nakaar · Carogen Corporation · R44 · FY2021 · DK
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure
$939,659Charles M. Rice · Rockefeller University · R01 · FY2019 · AI